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1. Introduction 
Hypertension (HT) and cardiovascular disease (CVD) are common in dialysis-dependent 
chronic kidney disease (DD-CKD) patients. The renin-angiotensin-aldosterone system 
(RAAS) plays pivotal roles in the pathogenesis of HT in DD-CKD patients. Activated 
RAAS also increases inflammatory mediators, which was shown to be an independent 
predictor of CVD in DD-CKD patients. Recent meta-analyses suggested that 
antihypertensive pharmacotherapy may reduce CVD in DD-CKD patients. This review 
focuses on the physiological roles and blockade effects of RAAS for HT and CVD in DD-
CKD patients.  
2. The physiological roles of RAAS in DD-CKD patients 
The role of RAAS in hypertensive DD-CKD patients was confirmed by the normalization 
of blood pressure (BP) upon administration of an angiotensin antagonist, saralasin. 
Normally, volume overload and elevation of BP result in suppression of RAAS 
production. Since this feedback is often incomplete in CKD patients, CKD patients often 
show HT and high or normal RAAS. Weidmann et al. reported that the renin levels of 
hypertensive hemodialysis-dependent CKD (HDD-CKD) patients were approximately 
twice as high as those of normal subjects. Parenchymal renal injury and renovascular 
disease may cause increased renin secretion in end-stage CKD. The prevalence of renal 
artery stenosis may be as high as 40% in patients starting HD, although the diagnosis was 
determined in only one-quarter of such a group before entering a dialysis program. 
Kimura et al. reported that plasma rennin activity (PRA) increased from 2.3±0.5 ng/ml/hr 
at just before initiation of HD to 6.5±1.3 ng/ml/hr over an 8- to 10-year period in HDD-
CKD patients. These data suggested that renin secretion continued even after disuse 
atrophy of kidney with almost complete deterioration of its excretory function.  
Activated RAAS increased inflammatory mediators, which is an independent risk factor for 
CVD. The mechanism is thought to be as follows. Activated RAAS directly increases pro-
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inflammatory gene expression and activates oxidative stress, leading to progressive 
inflammation of the vascular endothelium. In addition, among RAAS, mainly angiotensin II 
(AT II)  stimulates vascular reactive oxygen species (ROS) production from sources such as 
NADPH oxidase and uncoupled endothelial nitric oxide (NO) synthesis. Increased ROS 
down-regulates NO activity that leads to endothelial dysfunction. AT II also directly 
increases pro-inflammatory gene expressions, such as VCAM-1 and MCP-1. Both processes 
lead to further recruitment of inflammatory cells and accelerate the vascular inflammatory 
response. On the other hand, the prognostic value of a high plasma aldosterone 
concentration (PAC) in HDD-CKD patients is unknown, where PAC is known to be 
associated with poor outcome in patients with cardiac disease. Kohagura et al. reported that 
lower PAC was independently predictive of death in hypertensive DD-CKD patients. The 
adjusted hazard ratio (95% confidence interval) of the lower PAC group was 2.905 (1.187–
7.112, p=0.020). The significance of PAC became marginal when normalized with albumin or 
potassium. These results suggested that higher PAC was not associated with an increase in 
total and cardiovascular deaths among hypertensive HDD-CKD patients. The association 
between lower PAC and poor survival may be driven by volume retention and/or lower 
potassium level. Diskin et al. also reported that HDD-CKD patients with higher aldosterone 
levels tended to have longer survival.  
Recently, it was found that RAAS components are expressed in many tissues, such as the 
heart, kidney, placenta, testis, eye, and lymphocytes. These local tissue RAAS components 
are suggested to contribute to tissue damage. Prorenin, which is a biosynthetic precursor of 
renin, is secreted not only by the kidney but also by many other tissues, whereas circulating 
renin is derived exclusively from juxta-glomerular cells of the kidney. Prorenin does not 
have enzymatic activity itself; however, several studies have reported that circulating 
prorenin could be taken up by tissues and contribute to activating local RAAS by binding 
(pro)renin receptor [(P)RR] and then that inactive prorenin is converted to the active form, 
which obtains enzymatic activity by conformational change. Recent studies have 
demonstrated that prorenin-(P)RR interaction activated tissue RAAS and contributed to the 
pathogenesis of organ damage in several diseases, such as HT and diabetes end organ 
damage; however, few studies have reported the role of tissue RAAS and prorenin in DD-
CKD patients. Takemitsu et al. reported that arterial (P)RR may contribute to activate 
arterial tissue RAAS in HDD-CKD patients since arterial (P)RR mRNA expression was 
correlated with arterial angiotensin-converting enzyme (ACE) mRNA expression. 
Takemitsu et al. also reported that plasma prorenin concentration was correlated with PRA, 
plasma AT I level, plasma AT II level, and PAC level in HDD-CKD patients. Recently, we 
reported that the plasma prorenin level increased in HDD-CKD patients [147.1 +/- 118.9 
pg/ml (standard value <100 pg/ml)]. The (P)RR mRNA expression level in peripheral 
mononuclear cells (PBMCs) also increased 1.41 +/- 0.39-fold in HDD-CKD patients 
compared with that in healthy control subjects (p < 0.001) (Figure 1). Plasma prorenin 
significantly correlated with plasma 8-hydroxydeoxyguanosine (8-OHdG) level (r = 0.535, p 
< 0.001), which is a useful marker for assessment of oxidative DNA damage in reactive 
oxygen species (ROS) including in HDD-CKD patients (Figure 2). These results suggested 
that tissue RAAS activated by circulating prorenin contributes to the regulation of plasma 8-
OHdG level in HDD-CKD patients. 
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Fig. 1. (P)RR expression in peripheral blood mononuclear cells in healthy subjects (n=10) 
and HDD-CKD patients (n=49). Columns represent the mean ± s.e. (P)RR, prorenin receptor; 
HDD-CKD, hemodialysis-dependent chronic kidney disease (Morishita et al., 2011). 
 
Fig. 2. Correlations of plasma prorenin level and 8-OHdG in hemodialysis-dependent 
chronic kidney disease patients. 8-OHdG, 8-hydroxydeoxyguanosine (Morishita et al., 2011). 
3. The blocked effect of RAAS in DD-CKD patients  
3.1 HDD-CKD patients 
Angiotensin-converting enzyme inhibitors in HDD-CKD patients 
Tradolapril and captopril have been reported to be effective for HT in HDD-CKD patients. 
Zheng et al. reported that systolic BP (SBP) was decreased from 122.2±7.1 to 116.4±11.6 
mmHg and diastolic BP (DBP) was decreased from 75.3±10.4 to 70.4±11.4 mmHg after 2-10 
weeks by the administration of tradopril (2-8 mg/thrice a week (TIW)) after each HD 
session in 10 HDD-CKD patients. In that study, atenolol (25-50 mg/TIW) and/or 
amlodipine (10 mg/TIW) were also given if the patients had any member of these classes of 
drugs as part of their daily regimen. Wauterd et al. reported that captopril was administered 
www.intechopen.com
 
Novel Insights on Chronic Kidney Disease, Acute Kidney Injury and Polycystic Kidney Disease 
 
116 
orally in 2 daily doses of 25 to 200 mg in 8 HDD-CKD patients. These patients showed HT 
despite intensive ultrafiltration and conventional antihypertensive therapy. For 4 patients 
with the highest PRA, their BP was normalized by captopril alone. For the 4 remaining 
patients, captopril therapy was complemented by salt subtraction, which consisted of 
replacement of 1-2 liters of ultrafiltrate by an equal volume of 5% dextrose until BP was 
controlled. After an average treatment period of 5 months, BP of all 8 patients was reduced 
from 179/105 ± 6/3 (mean ±SEM) to 134/76 ± 7/5 mmHg (p <0.001) without a significant 
change in body weight. These clinical studies demonstrated that ACE inhibitor has 
beneficial effects to control BP in HDD-CKD patients. In addition, some studies reported 
that ACE inhibitors showed cardiovascular protective effects in HDD-CKD patients as 
follows. London et al. reported that perindopril (2-4 mg after each HD session) significantly 
reduced left ventricular mass (317±18 to 247±21 g, p=0.036) after 12 months in 14 HDD-CKD 
patients whereas a calcium channel antagonist, nitredipine (20-40 mg/day), did not when 
perindopril and nitredipine showed similar reductions of BP. Matsumoto et al. reported that 
imidapril (2.5 mg/day) significantly reduced left ventricular mass index (132±10 to 109±6 
g/m2, p<0.05) after 6 months; however, placebo did not produce a change in HDD-CKD 
patients. SBP and DBP were not significantly changed in either imidapril or placebo group. 
In that study, ACE was reduced (12±1 to 5±2 U/I, p<0.01) and PRA was increased (3.3±0.8 to 
8.1±3.2 ng/ml/h, p<0.01) but plasma AT II and aldosterone (Ald) were not significantly 
changed (13±3 to 17±3 pg/ml and 365±125 to 312±132 pg/ml, respectively). These results 
suggested that the beneficial effect of imidapril against left ventricular mass was 
independent of BP lowering effect. Zannad et al. reported that no significant benefit was 
found with fosinopril (5-20 mg/day) for the prevention of cardiovascular events such as 
cardiovascular death, resuscitated death, nonfatal stroke, heart failure, myocardial 
infarction, or revascularization in HDD-CKD patients; however, there was a trend that 
fosinopril treatment may be associated with a lower risk of cardiovascular events after 
adjustment for risk factors. These lines of evidence suggested that ACE inhibitors are 
effective in controlling BP and preventing CVD in HDD-CKD patients. It is highly likely that 
the cardioprotective effects of ACE inhibitors are independent of their BP lowering effect in 
HDD-CKD patients.   
Angiotensin receptor blockers in HDD-CKD patients 
Saracho et al. reported on a multicenter, open 6 month study designed to test the tolerability 
and efficacy of losartan as an antihypertensive in 406 hypertensive HDD-CKD  patients who 
were previously untreated, treated but uncontrolled, or treated with poor tolerability. There 
were significant reductions in pre- and postdialysis SBP and DBP at 3 months (pre 
SBP/DBP: 155 ± 15/84± 9 mmHg, post SBP/DBP: 140 ± 19/78± 10 mmHg) and 6 months 
(pre SBP/DBP: 152 ± 16/83± 9 mmHg, post SBP/DBP: 139± 18/77± 9 mm Hg) compared 
with those at baseline (pre SBP/DBP: 163 ± 16/88± 10 mmHg, post SBP/DBP: 148± 18/82± 9 
mmHg). Shibasaki et al. reported that losartan (50 mg/day) reduced left ventricular mass 
index (-24.7±3.2%) after 6 months more than a calcium channel antagonist, amlodipine (5 
mg/day: -10.5±5.2%), or an ACE inhibitor, enalapril (5 mg/day: -11.2±4.1%), although all 
three groups had similar decreases in mean BP. Kanno et al. reported that losartan (100 
mg/TIW) reduced left ventricular hypertrophy (145±5 to 122±3 g/m2, p<0.001) after 12 
months in 24 diabetic patients on HD therapy whereas a placebo group showed no change. 
In this study, SBP and DBP were controlled below 140/90 mmHg with a calcium antagonist, 
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benidipine (4-12 mg/day), and an α-blocker, doxazosin (2-4 mg/day). SPB was significantly 
decreased in both placebo and losartan groups after 12 months.These results suggested that 
this beneficial effect of losartan for left ventricular hypertrophy was independent of a BP 
lowering effect. Takahashi et al. stated that candesartan (4-8 mg/day) reduced 
cardiovascular events and mortality compared with placebo (16.3% vs. 45.9 and 0.0 vs. 
18.9%, respectively) after 19.4±1.2 months in HDD-CKD patients in a stable condition and 
with no clinical evidence of cardiac disorder. In this study, the brain natriuretic peptide 
(BNP) level did not differ between the two groups at enrolment, whereas in patients who 
had not experienced a cardiovascular event at 12 months, the BNP levels were significantly 
increased in the control group but not in the candesartan group. Suzuki et al. reported that 
angiotensin receptor blockers (ARBs) (valsartan: 160 mg/day, candesartan: 12 mg/day, or 
losartan: 100 mg/day) treatment was independently associated with reduced cardiovascular 
events (hazard ratio, 0.51; 95% confidence interval, 0.33 to 0.79; p=0.002) compared with no 
ARB treatment group for 180 HDD-CKD patients in each group during a 3 year observation 
period. There were 34 (19%) fatal or nonfatal CVD events in the ARBs group and 59 (33%) in 
the no ARB group. BP did not differ between the ARBs group and the no ARB group during 
the observation period. After adjustment for age, sex, diabetes, and SBP, treatment with an 
ARB was independently associated with reduced fatal and nonfatal CVD events (hazard 
ratio, 0.51; 95% confidence interval, 0.33 to 0.79; p=0.002). These results demonstrated that 
ARBs are effective in controlling BP and preventing CVD in HDD-CKD patients. We predict 
that the cardioprotective effects of ARBs may be independent of their BP lowering effect in 
HDD-CKD patients.   
Direct renin inhibitor  
An oral direct renin inhibitor, aliskiren, is effective against essential HT by reducing PRA, 
resulting in suppression of RAAS; however, little was known about the effects of aliskiren in 
HDD-CKD patients. Recently, we reported on antihypertensive and potential cardiovascular 
protective effects of aliskiren, in hypertensive HDD-CKD patients. Aliskiren (150 mg/day) 
significantly reduced SBP and DBP after 2 month in hypertensive HDD-CKD patients 
(Figure 3). RAAS was suppressed by aliskiren treatment (PRA: 3.6±4.0 to 1.0 ±1.5 ng/ml/hr, 
p=0.004; AT I: 1704.0±2580.9 to 233. 7±181.0 pg/ml, p=0.009; AT II: 70.2±121.5 to 12.4±11.5 
pg/ml, p=0.022) (Figure 4). Surrogate markers for cardiovascular disease such as BNP, high-
sensitivity CRP (hs-CRP), and an oxidative stress marker, diacron-reactive oxygen 
metabolite (d-ROM), were inhibited by aliskiren (BNP: 362.5±262.1 to 300.0±232.0 pg/ml, 
p=0.043; hs-CRP: 6.2±8.1 to 3.5±3.7 mg/l, p=0.022; d-ROM: 367.0±89.8 to 328.3±70.9 
U.CARR, p=0.022) (Figure 5). The levels of inhibition of these surrogate markers for CVD by 
aliskiren did not correlate with the decreased levels of BP. Two treatments were 
discontinued owing to an adverse event and symptomatic hypotension by aliskiren. The 
adverse event was eyebrow alopecia (1 patient). A possible connection of this event to 
aliskiren treatment could not be excluded. The symptomatic hypotension recovered to the 
basal level after aliskiren withdrawal. Increased serum potassium was not observed in any 
patients. Several studies reported that mean trough plasma aliskiren concentrations were 
increased by renal impairment; however, an increase in exposure did not correlate with the 
severity of renal impairment. Moreover, renal clearance of aliskiren was found to occur for 
only a small fraction (0.1-1.0%). These data suggest that adjustment of the aliskiren dose is 
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unlikely to be required in HDD-CKD patients. Further studies will be required to investigate 
the pharmacokinetics of aliskiren in HDD-CKD patients. In summary, these results suggest 
that aliskiren is effective in BP control and extend the possibility that aliskiren may have 
cardiovascular protective effects in hypertensive HDD-CKD patients. 
 
 
Fig. 3. Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from 
baseline (Week 0) to Week 8 with aliskiren (150 mg/day) treatment in hemodialysis-
dependent chronic kidney disease patients (Morishita et al., 2011a). 
 
Fig. 4. Change in plasma renin activity (PRA), angiotensin I (ATI), angiotensin II (ATII), and 
aldosterone (Ald) by aliskiren treatment in hemodialysis-dependent chronic kidney disease 
patients (Morishita et al., 2011a). 
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Fig. 5. Change in brain natriuretic peptide (BNP), highly sensitive C-reactive protein (hs-
CRP), and diacron-reactive oxygen metabolite (d-ROM) by aliskiren treatment in 
hemodialysis-dependent chronic kidney disease patients (Morishita et al., 2011a). 
3.2 PDD-CKD patients 
A few studies reported on a RAAS blockade effect in peritoneal dialysis-dependent CKD 
(PDD-CKD) patients. Fang et al. reported that a group (n=165) treated with ACE inhibitors/ 
ARBs had a significantly longer survival than an untreated group (n= 141) (log rank 19.191, 
P < 0.001) in PDD-CKD patients. After adjusting for age, BP, and other demographic and 
clinical parameters, multivariable Cox proportional hazards modeling showed that the use 
of ACE inhibitors/ARBs was associated with 62% reduced risk of death (HR 0.382, 95% CI 
0.232-0.631, P < 0.001) in PDD-CKD patients. Jing et al. reported that ultrafiltration of a 
group treated with ACE inhibitors/ARBs group (n=38) had not changed after 12 months 
whereas that of an untreated group (n=28) had decreased (P < 0.05). The expressions of 
fibronectin, Transforming growth factor-β1 (TGF-β1) and vascular endothelial growth 
factor (VEGF) in dialysate effluent were significantly increased in the untreated group, but 
not in the group treated with ACE inhibitors/ARBs. These results suggested that RAAS 
blockade has beneficial effects for mortality and peritoneal function in PDD-CKD patients. 
Suzuki et al. reported that ARB (valsartan) slowed the decline in residual renal function 
independent of BP lowering effect in PDD-CKD patinets.  
3.3 Caridioprotective effects of RAAS blockers independent of their BP lowering 
effect in DD-CKD patients 
Increasing evidence suggested that elevation of RAAS contributes directly to cardiac 
hypertrophy via its growth factor properties on smooth muscle cells and cardiac myocytes 
among DD-CKD patients, independent of BP effects. RAAS also plays a role in cardiac 
fibrosis by stimulating TGF-β1 gene expression and induction of fibroblast proliferation 
and collagen deposition. RAAS blockers may directly effects for cardiac hypertrophy and 
fibrosis via these pathways independent of their BP lowering effects in DD-CKD patients. In 
addition, several studies reported that RAAS blockers showed beneficial effects for pulse 
wave velocity which is recognized as a potent predictor of mortality in DD-CKD patients, 
independent of their BP lowering effects. Further studies will be needed to investigate the 
mechanism of cardioprotective effects of RAAS blockade on DD-CKD patients.  
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3.4 Adverse effects of RAAS blockers in DD-CKD patients 
ACE inhibitors showed several adverse effects in HDD-CKD patients. High-dose ACE 
inhibitors suppressed erythropoiesis and induced resistance to erythropoietin therapy in 
HDD-CKD patients. Occasionally, ACE inhibitors may cause anaphylactoid reactions with 
AN69 dialysis membrane in HDD-CKD patients by elevation of bradykinin level (Kammerl 
et al., 2000). Hyperkalemia, which is a frequent concern in HDD-CKD patients 
independently of medication use, is the primary danger from RAAS blocking medications. 
Several clinical trials of ACE inhibitors, ARBs, and renin inhibitor in HDD-CKD patients 
tracked potassium levels. Increased hyperkalemia by these RAAS blockers in HDD-CKD 
patients was not observed in these trials. These results suggested that the risk of 
hyperkalemia by RAAS blocking is small.   
4. Conclusion  
From previous studies, it is suggested that RAAS blockade has a beneficial effect in 
controlling BP and preventing CVD in DD-CKD patients. However, the choice of the RAAS 
inhibitor as well as its use in the treatment of DD-CKD patients have to be carefully 
determined considering the possible adverse effects and potential interactions with other 
drugs being used in the treatment of DD-CKD patients. Further studies with an adequate 
sample size and a thorough design are still needed to determine the effect of RAAS blockade 
on DD-CKD patients.  
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